-+ 0.00%
-+ 0.00%
-+ 0.00%

Phathom Pharmaceuticals presents new VOQUEZNA analyses in GERD at ACG 2026 meeting

PUBT·10/08/2026 12:02:30
Listen to the news
Phathom Pharmaceuticals presents new VOQUEZNA analyses in GERD at ACG 2026 meeting
  • Phathom flagged new analyses for its GERD drug VOQUEZNA ahead of the American College of Gastroenterology 2026 meeting in Nashville.
  • Results have not been presented yet; posters are scheduled for Oct. 11-13, with a product theater on Oct. 12.
  • Data focus on real-world patient profiles, symptom relief across weight groups, and an economic model versus proton pump inhibitors in erosive disease.
  • The readouts aim to support positioning in a crowded reflux market, with emphasis on where VOQUEZNA may fit in treatment decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841816) on October 08, 2026, and is solely responsible for the information contained therein.